{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:37:50Z","timestamp":1792190270587,"version":"4.4.0"},"reference-count":81,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n In the era of sodium-glucose cotransporter 2 (SGLT2) inhibitors, population-wide screening for chronic kidney disease (CKD) may provide good value, yet implications across racial and ethnic groups are unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the health outcomes, costs, and cost-effectiveness of population-wide CKD screening for 4 racial and ethnic groups.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this cost-effectiveness analysis, a decision-analytic Markov model was separately calibrated to simulate CKD progression among simulated cohorts of US Hispanic adults, non-Hispanic Black adults, non-Hispanic White adults, and adults who belong to additional racial and ethnic groups (ie, Asian and multiracial individuals and those self-reporting other race and ethnicity). Effectiveness of SGLT2 inhibitors was derived from the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease trial. Mortality, quality-of-life weights, and cost estimates were obtained from published cohort studies, randomized clinical trials, and Centers for Medicare &amp;amp; Medicaid Services data. Analyses were conducted from January 1, 2023, to November 6, 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n One-time or periodic (every 10 or 5 years) screening for albuminuria, initiated between age 35 and 75 years, with and without addition of SGLT2 inhibitors to angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker therapy for CKD.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Lifetime cumulative incidence of kidney failure requiring kidney replacement therapy (KRT); discounted life-years (LYs), quality-adjusted LYs (QALYs), lifetime health care costs (in 2024 US dollars), and incremental cost-effectiveness ratios.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Under the status quo, non-Hispanic Black adults aged 35 years had the highest lifetime incidence of kidney failure requiring KRT (6.2% [95% UI, 2.8%-10.6%]) compared with Hispanic adults (3.6% [95% UI, 1.1%-6.7%]), non-Hispanic White adults (2.3% [95% UI, 0.4%-5.2%]), and adults from additional racial and ethnic groups (3.3% [95% UI, 1.2%-6.5%]). Screening every 5 years from ages 55 to 75 years combined with SGLT2 inhibitors reduced incidence of KRT and increased LYs across all racial and ethnic groups, with the largest average changes observed for non-Hispanic Black adults (0.8\u2013percentage point decrease and 0.19-year increase). Every 5-year screening from age 55 to 75 years cost $99\u202f100\/QALY gained for the overall population and less than $150\u202f000\/QALY gained across racial and ethnic groups, with the lowest cost observed for non-Hispanic Black adults ($73\u202f400\/QALY gained). Screening starting at age 35 years was only cost-effective for non-Hispanic Black adults ($115\u202f000\/QALY gained).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cost-effectiveness analysis, population-wide screening for CKD from ages 55 to 75 years was projected to improve population health, was cost-effective, and reduced disparities across 4 racial and ethnic groups. Starting population-wide screening at younger ages was projected to further benefit non-Hispanic Black adults.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.4740","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T11:00:34Z","timestamp":1744628434000},"page":"e254740","source":"Crossref","is-referenced-by-count":10,"title":["Balancing Efficiency and Equity in Population-Wide CKD Screening"],"prefix":"10.1001","volume":"8","author":[{"given":"Marika M.","family":"Cusick","sequence":"first","affiliation":[{"name":"Department of Health Policy, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Tisdale","sequence":"additional","affiliation":[{"name":"Veterans Affairs Palo Alto Health Care System, Palo Alto, California"},{"name":"Division of Primary Care and Population Health, Department of Medicine, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyce S.","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Health Policy, School of Medicine, Stanford University, Stanford, California"},{"name":"Department of Epidemiology and Population Health, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[{"name":"Department of Health Policy, School of Medicine, Stanford University, Stanford, California"},{"name":"Division of Nephrology, Department of Medicine, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas K.","family":"Owens","sequence":"additional","affiliation":[{"name":"Department of Health Policy, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Salomon","sequence":"additional","affiliation":[{"name":"Department of Health Policy, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Goldhaber-Fiebert","sequence":"additional","affiliation":[{"name":"Department of Health Policy, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"issue":"5","key":"zoi250210r3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.semnephrol.2013.07.002","article-title":"Racial disparities in kidney disease outcomes.","volume":"33","author":"Nicholas","year":"2013","journal-title":"Semin Nephrol"},{"issue":"6","key":"zoi250210r4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1053\/j.ajkd.2016.05.030","article-title":"Risk of ESRD in the United States.","volume":"68","author":"Albertus","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"zoi250210r5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.ajkd.2018.02.354","article-title":"CKD and ESRD in US Hispanics.","volume":"73","author":"Desai","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"zoi250210r6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2369-9-3","article-title":"A systematic review of patient and health system characteristics associated with late referral in chronic kidney disease.","volume":"9","author":"Navaneethan","year":"2008","journal-title":"BMC Nephrol"},{"issue":"9","key":"zoi250210r7","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1681\/ASN.2016010027","article-title":"Social determinants of racial disparities in CKD.","volume":"27","author":"Norton","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"zoi250210r8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.12.015","author":"Jurkovitz","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"zoi250210r9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/ndt\/gfq473","article-title":"Race differences in access to health care and disparities in incident chronic kidney disease in the US.","volume":"26","author":"Evans","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"zoi250210r10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2310\/JIM.0b013e31819dbb91","article-title":"Social environmental stressors, psychological factors, and kidney disease.","volume":"57","author":"Bruce","year":"2009","journal-title":"J Investig Med"},{"issue":"11","key":"zoi250210r11","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1136\/jech-2018-210665","article-title":"Racial disparities in renal function: the role of racial discrimination.","volume":"72","author":"Camelo","year":"2018","journal-title":"J Epidemiol Community Health"},{"issue":"2","key":"zoi250210r12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1681\/ASN.2006080934","article-title":"Neighborhood poverty and racial differences in ESRD incidence.","volume":"19","author":"Volkova","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"zoi250210r13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1053\/j.ackd.2014.05.005","article-title":"Contextual poverty, nutrition, and chronic kidney disease.","volume":"22","author":"Guti\u00e9rrez","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"issue":"8","key":"zoi250210r14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.7326\/0003-4819-157-8-201210160-00533","article-title":"Screening for chronic kidney disease: US Preventive Services Task Force recommendation statement.","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"issue":"15","key":"zoi250210r15","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"4S","key":"zoi250210r16","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"issue":"6","key":"zoi250210r17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.7326\/M22-3228","article-title":"Population-wide screening for chronic kidney disease: a cost-effectiveness analysis.","volume":"176","author":"Cusick","year":"2023","journal-title":"Ann Intern Med"},{"issue":"11","key":"zoi250210r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.3892","article-title":"Population-wide screening for chronic kidney disease: a cost-effectiveness analysis.","volume":"5","author":"Cusick","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"1","key":"zoi250210r19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"20","author":"Husereau","year":"2022","journal-title":"BMC Med"},{"issue":"19","key":"zoi250210r21","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin c-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"9176","key":"zoi250210r22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"issue":"12","key":"zoi250210r23","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi250210r24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency.","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi250210r25","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.","volume":"18","author":"Hou","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"zoi250210r26","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jaip.2013.07.005","article-title":"ACE inhibitor-induced angioedema.","volume":"1","author":"Baram","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"zoi250210r27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001007","article-title":"Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.","volume":"2","author":"Clar","year":"2012","journal-title":"BMJ Open"},{"issue":"13","key":"zoi250210r28","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1007\/s11606-021-07311-5","article-title":"Cost-effectiveness of dapagliflozin for non-diabetic chronic kidney disease.","volume":"37","author":"Tisdale","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"6","key":"zoi250210r29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.7326\/0003-4819-159-6-201309170-00004","article-title":"Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.","volume":"159","author":"Erickson","year":"2013","journal-title":"Ann Intern Med"},{"issue":"13","key":"zoi250210r30","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi250210r32","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1681\/ASN.2019121308","article-title":"Health care costs by type of expenditure across eGFR stages among patients with and without diabetes, cardiovascular disease, and heart failure.","volume":"31","author":"Nichols","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"zoi250210r36","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"zoi250210r37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s13300-018-0371-y","article-title":"Cost-effectiveness analysis of canagliflozin 300 mg versus dapagliflozin 10 mg added to metformin in patients with type 2 diabetes in the United States.","volume":"9","author":"Neslusan","year":"2018","journal-title":"Diabetes Ther"},{"issue":"1","key":"zoi250210r38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40842-021-00127-6","article-title":"Recurrent DKA results in high societal costs\u2014a retrospective study identifying social predictors of recurrence for potential future intervention.","volume":"7","author":"Lyerla","year":"2021","journal-title":"Clin Diabetes Endocrinol"},{"issue":"1","key":"zoi250210r40","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12955-020-01559-x","article-title":"Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review.","volume":"18","author":"Cooper","year":"2020","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"zoi250210r41","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0272989X06290497","article-title":"Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores.","volume":"26","author":"Hanmer","year":"2006","journal-title":"Med Decis Making"},{"issue":"8","key":"zoi250210r42","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamacardio.2016.3517","article-title":"Cost-effectiveness of intensive blood pressure management.","volume":"1","author":"Richman","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"8","key":"zoi250210r43","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jval.2016.05.018","article-title":"EQ-5D scores for diabetes-related comorbidities.","volume":"19","author":"Sullivan","year":"2016","journal-title":"Value Health"},{"issue":"8","key":"zoi250210r44","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1177\/0272989X16658660","article-title":"The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes.","volume":"36","author":"Peasgood","year":"2016","journal-title":"Med Decis Making"},{"issue":"7","key":"zoi250210r45","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamainternmed.2014.1363","article-title":"Diagnostic performance of random urine samples using albumin concentration vs ratio of albumin to creatinine for microalbuminuria screening in patients with diabetes mellitus: a systematic review and meta-analysis.","volume":"174","author":"Wu","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"9","key":"zoi250210r47","doi-asserted-by":"publisher","first-page":"660","DOI":"10.7326\/0003-4819-131-9-199911020-00005","article-title":"The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.","volume":"131","author":"Golan","year":"1999","journal-title":"Ann Intern Med"},{"issue":"23","key":"zoi250210r48","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1001\/jama.290.23.3101","article-title":"Screening for proteinuria in US adults: a cost-effectiveness analysis.","volume":"290","author":"Boulware","year":"2003","journal-title":"JAMA"},{"issue":"8","key":"zoi250210r51","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1177\/0272989X15605091","article-title":"Some health states are better than others: using health state rank order to improve probabilistic analyses.","volume":"36","author":"Goldhaber-Fiebert","year":"2016","journal-title":"Med Decis Making"},{"issue":"3","key":"zoi250210r52","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2165\/00002018-199818030-00003","article-title":"ACE inhibitor-induced angioedem: incidence, prevention and management.","volume":"18","author":"Vleeming","year":"1998","journal-title":"Drug Saf"},{"issue":"2","key":"zoi250210r53","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s13300-018-0371-y","article-title":"Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.","volume":"9","author":"Neslusan","year":"2018","journal-title":"Diabetes Ther"},{"issue":"1","key":"zoi250210r54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40842-021-00127-6","article-title":"Recurrent DKA results in high societal costs - a retrospective study identifying social predictors of recurrence for potential future intervention.","volume":"7","author":"Lyerla","year":"2021","journal-title":"Clin Diabetes Endocrinol"},{"issue":"6","key":"zoi250210r55","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study.","volume":"173","author":"Douros","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi250210r57","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/1475-6773.12612","article-title":"Adjusting health expenditures for inflation: a review of measures for health services research in the United States.","volume":"53","author":"Dunn","year":"2018","journal-title":"Health Serv Res"},{"issue":"4","key":"zoi250210r59","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0272989X9701700414","article-title":"Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means.","volume":"17","author":"Stinnett","year":"1997","journal-title":"Med Decis Making"},{"issue":"7","key":"zoi250210r60","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1177\/0272989X13492014","article-title":"Linear regression metamodeling as a tool to summarize and present simulation model results.","volume":"33","author":"Jalal","year":"2013","journal-title":"Med Decis Making"},{"issue":"10365","key":"zoi250210r61","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"zoi250210r62","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250210r63","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/M20-1392","article-title":"A health opportunity cost threshold for cost-effectiveness analysis in the United States.","volume":"174","author":"Vanness","year":"2021","journal-title":"Ann Intern Med"},{"issue":"7","key":"zoi250210r64","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jval.2019.03.003","article-title":"A new method to determine the optimal willingness to pay in cost-effectiveness analysis.","volume":"22","author":"Phelps","year":"2019","journal-title":"Value Health"},{"issue":"7","key":"zoi250210r66","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1681\/ASN.2008030276","article-title":"Race, gender, and socioeconomic disparities in CKD in the United States.","volume":"19","author":"Norris","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"zoi250210r67","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2215\/CJN.12710820","article-title":"Social determinants of kidney health: focus on poverty.","volume":"16","author":"Norris","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"zoi250210r68","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","article-title":"The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"zoi250210r69","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1053\/j.ajkd.2016.01.022","article-title":"Educational interventions for patients with CKD: a systematic review.","volume":"68","author":"Lopez-Vargas","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"zoi250210r71","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/MLR.0000000000001133","article-title":"A randomized study of values affirmation to promote interest in diabetes prevention among women with a history of gestational diabetes.","volume":"57","author":"Brown","year":"2019","journal-title":"Med Care"},{"issue":"7","key":"zoi250210r72","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/tbm\/ibac019","article-title":"Reach, acceptability, and perceived success of a telehealth diabetes prevention program among racially and ethnically diverse patients with gestational diabetes: the GEM cluster-randomized trial.","volume":"12","author":"Brown","year":"2022","journal-title":"Transl Behav Med"},{"issue":"1","key":"zoi250210r74","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41581-023-00784-z","article-title":"Differences in the epidemiology, management and outcomes of kidney disease in men and women.","volume":"20","author":"Chesnaye","year":"2024","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"zoi250210r75","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi250210r76","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi250210r77","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250210r78","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1053\/j.ajkd.2014.09.023","article-title":"The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative.","volume":"65","author":"Hoerger","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"zoi250210r79","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/ndt\/gfn082","article-title":"A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.","volume":"23","author":"Palmer","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"21","key":"zoi250210r80","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"zoi250210r1","unstructured":"Centers for Disease Control and Prevention. Chronic kidney disease surveillance system. Accessed November 18, 2020. https:\/\/nccd.cdc.gov\/ckd\/"},{"key":"zoi250210r2","unstructured":"United States Renal Data System. 2023 USRDS annual data report: epidemiology of kidney disease in the United States. Accessed March 5, 2025. https:\/\/usrds-adr.niddk.nih.gov\/2023"},{"key":"zoi250210r20","unstructured":"US Centers for Disease Control and Prevention, National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey data. Accessed March 5, 2025. https:\/\/www.cdc.gov\/nchs\/nhanes\/"},{"key":"zoi250210r31","unstructured":"Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey (MEPS). July 2024. Accessed March 5, 2025. https:\/\/www.ahrq.gov\/data\/meps.html"},{"key":"zoi250210r33","unstructured":"United States Renal Data System. 2020 USRDS annual data report: epidemiology of kidney disease in the United States. Accessed March 9, 2021. https:\/\/usrds-adr.niddk.nih.gov\/2020"},{"key":"zoi250210r34","unstructured":"Data.CMS.gov. Medicare Part D spending by drug. Accessed October 23, 2024. https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-d-spending-by-drug"},{"key":"zoi250210r35","unstructured":"Centers for Medicare & Medicaid Services. Medicare drug price negotiation program: negotiated prices for initial price applicability year 2026. Accessed October 23, 2024. https:\/\/www.cms.gov\/newsroom\/fact-sheets\/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026"},{"key":"zoi250210r39","unstructured":"Centers for Medicare & Medicaid Services. Files for FY 2010 final rule and correction notice. Accessed March 5, 2025. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/AcuteInpatientPPS\/Acute-Inpatient-Files-for-Download-Items\/CMS1247873"},{"key":"zoi250210r46","doi-asserted-by":"crossref","unstructured":"Creatinine, 24-hour urine in online lab tests stores. Accessed June 27, 2022. https:\/\/www.findlabtest.com\/lab-test\/kidney-function-test\/creatinine-24-hour-urine-quest-381","DOI":"10.1097\/00152193-199406000-00014"},{"key":"zoi250210r49","unstructured":"Serum creatinine test cost. Accessed June 27, 2022. https:\/\/www.findlabtest.com\/lab-test\/kidney-function-test\/serum-creatinin.e-test-cost-quest-375"},{"key":"zoi250210r50","unstructured":"New Choice Health. Abdominal ultrasound cost and procedure comparison. Accessed June 28, 2022. https:\/\/www.newchoicehealth.com\/procedures\/abdominal-ultrasound"},{"key":"zoi250210r56","unstructured":"Agency for Healthcare Research and Quality. Information on the health status of Americans, health insurance coverage, and access, use, and cost of health services. Accessed March 10, 2025. https:\/\/datatools.ahrq.gov\/meps-hc\/"},{"key":"zoi250210r58","unstructured":"Agency for Healthcare Research and Quality. Using appropriate price indices for expenditure comparisons. Accessed January 20, 2023. https:\/\/www.meps.ahrq.gov\/about_meps\/Price_Index.shtml"},{"key":"zoi250210r65","unstructured":"Institute for Clinical and Economic Review. Overview of the ICER value assessment framework for 2017-2019. May 8, 2018. Accessed March 5, 2025. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER-value-assessment-framework-Updated-050818.pdf"},{"key":"zoi250210r70","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. National kidney disease education program. Accessed October 25, 2024. https:\/\/www.niddk.nih.gov\/health-information\/community-health-outreach\/information-clearinghouses\/nkdep"},{"key":"zoi250210r73","doi-asserted-by":"crossref","unstructured":"Lawrenson? JG, Graham-Rowe? E, Lorencatto? F, . Interventions to increase attendance for diabetic retinopathy screening. Cochrane Database of Systematic Reviews. Published online January 15, 2018. Accessed October 28, 2024. https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012054.pub2\/full","DOI":"10.1002\/14651858.CD012054.pub2"},{"key":"zoi250210r81","doi-asserted-by":"crossref","unstructured":"Koshino? A, Schechter? M, Chertow? GM, . Dapagliflozin and anemia in patients with chronic kidney disease. NEJM Evidence. 2023;2(6):EVIDoa2300049. doi:10.1056\/EVIDoa2300049","DOI":"10.1056\/EVIDoa2300049"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2832754\/cusick_2025_oi_250210_1744121509.78611.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T11:00:40Z","timestamp":1744628440000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2832754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.4740","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}